CN1507875A - Tumour gene switch medicine - Google Patents
Tumour gene switch medicine Download PDFInfo
- Publication number
- CN1507875A CN1507875A CNA2003101135402A CN200310113540A CN1507875A CN 1507875 A CN1507875 A CN 1507875A CN A2003101135402 A CNA2003101135402 A CN A2003101135402A CN 200310113540 A CN200310113540 A CN 200310113540A CN 1507875 A CN1507875 A CN 1507875A
- Authority
- CN
- China
- Prior art keywords
- sequence
- nucleic acid
- medicine
- cell
- decoy nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 title abstract description 31
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 69
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 69
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 69
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 230000002068 genetic effect Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 4
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000012512 characterization method Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 34
- 210000004881 tumor cell Anatomy 0.000 abstract description 16
- 230000014509 gene expression Effects 0.000 abstract description 15
- 230000012010 growth Effects 0.000 abstract description 8
- 108700019961 Neoplasm Genes Proteins 0.000 abstract 2
- 102000048850 Neoplasm Genes Human genes 0.000 abstract 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 description 44
- 229940079593 drug Drugs 0.000 description 16
- 102100023132 Transcription factor Jun Human genes 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 108700020978 Proto-Oncogene Proteins 0.000 description 8
- 102000052575 Proto-Oncogene Human genes 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 230000002018 overexpression Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 7
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 7
- 102100027584 Protein c-Fos Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 6
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 6
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 6
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 4
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 231100000636 lethal dose Toxicity 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 101710090875 Protein c-Fos Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 102000005869 Activating Transcription Factors Human genes 0.000 description 2
- 108010005254 Activating Transcription Factors Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 241000514744 Cyclina Species 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108091035710 E-box Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008846 Neurocytoma Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 1
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000010266 Sephadex chromatography Methods 0.000 description 1
- 102100022056 Serum response factor Human genes 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 108050005223 Transcription factor Jun Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000006642 detritylation reaction Methods 0.000 description 1
- -1 diisopropyl β-cyanoethyl phosphoramidite Chemical compound 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000001225 nuclear magnetic resonance method Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a tumor gene switch medicine formed from a segmentum of sequence specific decoy nucleic acid. Said nucleic acid can specially be combined with transcriptional regulation and control factor of some cancer genes in the cell, and can resist the excessive expression of these cancer genes to inhibit the growth of the tumor cell, so that it can be developed into the medicine for gene curing tumor.
Description
Technical field:
Anti-tumor medicine.
Background technology:
From molecular level, tumor relates to the movable unusual disease of polygenes, and every kind of tissue canceration or every kind of cell phenotype all relate to tens of and even hundreds of gene activities.Still indeterminate which gene as the treatment target spot.But tentatively distinct now, tumor be to carry out the rapid multistage of multistep.Have preface in vain with a certain cell phenotype related gene group's activity on time and carry out, the tandem type expression rule is arranged, the activity that is in the functional gene in tandem type downstream is controlled by the controlling gene of upstream.Therefore, the controlling gene by changing the upstream movable unusual still can be controlled whole downstream gene group's activity, and then make cell phenotype return to optimum phenotype from the malignant phenotype, reaches the purpose of curing tumor.
The controlling gene of upstream promptly is the gene of express cell nuclear factor (DNA is conjugated protein), comprises that relevant proto-oncogene and antioncogene take place tumor.Because under some extraneous factor effect, proto-oncogene activates and the inactivation of overexpression and antioncogene.Be that disorder out of control takes place controlling gene, expression regulation own is not normal, and causes other downstream gene regulation and control and express not normal chain reaction, causes tumor to take place, and therefore, proto-oncogene, antioncogene are the important target spots of therapy of tumor.
Feature of tumor cell is the proto-oncogene overexpression, wherein c-myc all has high expressed in kinds of tumors such as myelogenous leukemia, B lymphoma, T lymphoma, sarcomas, and in leukemia, breast carcinoma, gastric cancer, small cell lung cancer, colon cancer, neurocytoma, glioblastoma multiforme, retinoblastoma cell cancer amplification is in various degree arranged all.Cause overexpression at the human liver cancer cell hypomethylation.C-fos is in overexpressions such as osteosarcoma, lymphoma.C-jun is at cellule type lung tumor and lung cancer in non-cellule type, colorectal carcinoma high expressed.In the startup of tumor, short tumor stage, the high expressed (taking place relevant with tumor) of c-myc, c-jun is arranged.
Tumor cell another feature: the lost cell period specific lose the respond of on cell proliferation signal, and the c-myc overexpression is one of prerequisite of cell proliferation.The MYC-MAX heterodimer is incorporated into E-box, and expression such as activation itself and downstream communication gene C YC25A form the cell proliferation phenotype, and with the E2F combined effect, activate cyclinA, cyclin E, G1 in cell cycle → conversion of S phase is to play a crucial role.C-myc also can activate the expression of telomerase, forms in the promotion tumor to play an important role.C-jun and c-fos play an important role in the nuclear phase of the downstream of RAS signal transduction path.(being called as early stage fast reaction gene or third messenger).C-myc and c-fos play an important role in cell differentiation.In addition, play an important role in c-myc, c-fos, c-jun, the cell maturation stable at apoptosis, genome.Therefore, the regulation and control that change c-myc, c-fos, c-jun are unusual, are optimum phenotype thereby can change the malignant proliferation phenotype,
Proto-oncogene and antioncogene exist simultaneously at normal cell and tumor cell, the expression degree difference that different is in the two class cells, and tumor cell is the proto-oncogene overexpression, is Normocellular 2～10 times, and the antioncogene inactivation.These explanation expression of gene regulation and control have occurred unusual, this be unusually cis-trans factor bonding state and quantity on the control region of gene generation change, how to eliminate this unusual, change the gene regulation state, at present a kind of new strategy being arranged in the world is transcription factor " bait " method (decoy), with specific DNA sequence in conjunction with transcription regulatory factor (comprising transcription inhibition factor on the activating transcription factor on the enhancer and antioncogene silencer on the proto-oncogene), change the expression status of controlling gene, thereby change cell phenotype.
People are in the basic research of DNA and protein interaction relation, find and confirm: external synthetic one section sequence-specific short chain DNA, can combine with a certain factor in the nucleus protein extract, in polyacrylamide gel electrophoresis, produce the gel inhibition phenomena, provide experiment basis for present decoy nucleic acid develops into medicine.Since the nineties, Bielinska (1990) has proposed with since the double-stranded nucleic acid oligomer regulate gene expression, decoy nucleic acid at first is used in the exploitation of treatment cardiovascular drugs, neointimal hyperplasia (Mann.et al1999) with the decoy exonuclease treatment venous bypass postoperative blood vessel of the E2F factor has entered clinical, prevent and treat myocardial infarction (Sawa.1997.Tounita.1998) with the decoy nucleic acid of NF-Kappa β, also have the decoy nucleic acid of AGE, SRF etc.Decoy nucleic acid is applied to oncotherapy and just has been in the starting stage, as: the decoy nucleic acid of the CREB factor (Cho-chong 1999) is carried out in various tumor cell strains and animal model.The decoy nucleic acid of ER (PivaR et al2000) is used to suppress the breast cancer cell growth.The decoy nucleic acid of NF-Kappa β (Sharma.HW etal) is obtained certain inhibition effect at mice fibroma internal and external test.
Summary of the invention:
One of purpose of the present invention provides genetic switch medicine for treating tumor, it is characterized in that a series of sequence-specific decoy nucleic acid, but specificity is in conjunction with transcription regulatory factor separately.Oncogene c-fos, c-jun, the c-myc of downward modulation overexpression, thus the malignant proliferation of inhibition tumor cell reaches the purpose for the treatment of tumor.
Another object of the present invention provides and contains decoy nucleic acid medicine composition of the present invention.
Another object of the present invention is the purposes that decoy nucleic acid of the present invention is used to prepare antitumor drug.
Purpose of the present invention can reach by following measure:
The design of genetic switch medicine for treating tumor is with the sequence of the transcription factor specific bond core sequence as medicine decoy nucleic acid, and suitably increase the flank length of core sequence, make it easily form space structure, stability of drug reaches and the affinity of the target factor to strengthen.
Medicine KGCD101A series is to design for the overexpression of regulating and control proto-oncogene C-FOS.Control region according to proto-oncogene C-FOS combines a plurality of factors, as: SRF, CREB, AP-1, the SIF factor etc., wherein the binding site CRE enhancer sequence STGACGTMR (sequence 1) of the CREB factor is as the core sequence of medicine decoy nucleic acid, competition is reduced the expression of proto-oncogene C-FOS in conjunction with CREB.For example: medicine KGCD101a (sequence 6) is made up of 34 nucleotide, contains this core sequence, and has hairpin structure.For another: medicine KGCD101a-1 also can be made up of sequence 7 that contains this core sequence and sequence 8,48 nucleotide, two sequences are combined in the double-stranded process and form decussate texture.Medicine KGCD101a-2 forms T shape structure by sequence 7 and sequence 9.In a word, this class decoy nucleic acid drug, can be designed as with STGACGTMR is core sequence, nucleotide adds up to 15-55.And easily form the short chain dna molecular of hair clip, false knot, stem ring, dumbbell, the multiple secondary structure of cross.
Medicine KGCD101B and KGCD101C series design for regulating and control multiple proto-oncogene.FOS-JUN forms heterodimer, becomes the AP-1 activating transcription factor, and it is incorporated on the cis element STGASTMA (sequence 2) of a plurality of genes, activates the expression of several genes.Adopting this sequence is the core sequence of medicine decoy nucleic acid, and downward modulation contains AP-1 enhancer expression of gene, thereby suppresses the growth of tumor cell.For example: medicine KGCD101b is made of sequence 10 and sequence 11, contains this core sequence, and nucleotide adds up to 42 double chain DNA molecule.Medicine KGCD101b-1 (sequence 12) has 35 nucleotide and contains this core sequence, has hairpin structure.Medicine KGCD101b-2 (sequence 13) has 42 nucleotide and contains this core sequence, has the dumbbell structure, available ligase makes 5 ' and 3 ' end connect into closed loop, to increase medicine stability.Medicine KGCD101C is made up of sequence 14 and sequence 15, and its nucleotide adds up to 42, contains this core sequence, has decussate texture.Medicine KGCD101c1 is made up of sequence 16 and sequence 17, and its nucleotide adds up to 44, contains this core sequence, has decussate texture.In a word, this class decoy nucleic acid drug, can be designed as with STGASTMA (sequence 2) is core sequence, nucleotide adds up to 15-55 ' and the easy short chain dna molecular that forms hair clip, false knot, stem ring, dumbbell, the multiple secondary structure of cross.
Medicine KGCD102 series designs for the regulation and control proto-oncogene c-jun.Effect according to c-jun autoactivation expression.The enhancer sequence TTACCTCA of c-jun protein binding autogene (sequence 3), this sequence is as the core sequence of the decoy nucleic acid of medicine KGCD102 series, and downward modulation c-jun expresses.For example medicine KGCD102 (sequence 18) is for containing this core sequence, and nucleotide adds up to 37, has one of this type of decoy nucleic acid drug of hairpin structure.Other has medicine KGCD102-1 (sequence 19) is 40 nucleotide, has hairpin structure.Medicine KGCD102-2 (sequence 20) is 38 nucleotide, has the dumbbell structure.Medicine KGCD102-3 (sequence 21 and sequence 22) is 54 nucleotide, has loop-stem structure.In a word, this class decoy nucleic acid drug, can be designed as with TTACCTCA (sequence 3) is core sequence, nucleotide adds up to 15-55, and easily forms the short chain dna molecular of hair clip, false knot, stem ring, dumbbell, the multiple secondary structure of cross.
Medicine KGCD103a series designs for regulation and control proto-oncogene C-MYC.Combine with self enhancer TCTCTTA (sequence 4) sequence according to C-MYC, with the basic composition of this core sequence as the decoy nucleic acid drug, downward modulation C-MYC gene expression.For example: medicine KGCD103a is by sequence 23: and sequence 24 forms: and double-stranded DNA is formed, and 52 nucleotide contain this core sequence.Medicine KGCD103a-1 (sequence 25) has 35 nucleotide that contain this core sequence, hairpin structure.Medicine KGCD103a-2 is formed by sequence 26 and sequence 27: loop-stem structure is formed, and 43 nucleotide contain this core sequence.Medicine KGCD103a-3 is made up of the capitate structure that sequence 28 and sequence 29 form, and 36 nucleotide contain this core sequence.In a word, this class decoy nucleic acid drug, can be designed as with TCTCTTA (sequence 4) is core sequence, nucleotide adds up to 15-55, and easily forms the short chain dna molecular of hair clip, false knot, stem ring, dumbbell, the multiple secondary structure of cross.
Medicine KGCD103b is for the dependency basis of regulation and control control cell cycle thereby design.Promote cell proliferation according to the MYC-MAX heterodimer, make cell lose period specific, cis element RACCACGTGGTY (sequence 5) is as the core sequence of decoy nucleic acid, external synthetic and transfered cell, combine the compound dimer of MYC-MAX with the cis element competition of gene itself, suppress downstream gene expression, change the malignant proliferation phenotype.For example: medicine KGCD103b (sequence 30) is 32 nucleotide, contains this core sequence.The cross structure that medicine KGCD103b-1 is formed by sequence 31 and sequence 32,47 nucleotide contain this core sequence.In a word, this class decoy nucleic acid drug, can be designed as with RACCACGTGGTY (sequence 5) is core sequence, nucleotide adds up to 15-55, and easily forms the short chain dna molecular of hair clip, false knot, stem ring, dumbbell, the multiple secondary structure of cross.
The decoy nucleic acid drug is synthetic through the full-automatic synthesizer of DNA, thioated, deprotection; purification and lyophilizing; soluble in water, behind the quantitative and qualitative determination and analysis, carry out the in-vitro screening and the test of pesticide effectiveness; with the NCI-H460 lung carcinoma cell as the screening system; cell is added 96 well culture plates, behind RPMI 1640 complete culture solutions cultivation 24h, add liposome and above-mentioned decoy nucleic acid; continue at 37 ℃, 5%CO
2The middle 48h that cultivates.Survival rate with SRB colorimetric method for determining cell.The selection result shows that six kinds of decoy nucleic acid all have in various degree inhibitory action, wherein the inhibitory action maximum of KGCD101a and KGCD102 to the NCI-H460 cell.These decoy nucleic acid all can be developed into and are antitumor drug.
Advantage of the present invention:
Decoy nucleic acid is different with antisensenucleic acids, and structural difference is: antisensenucleic acids is the linear nucleic acid oligomer of strand, and decoy nucleic acid can form double-stranded and tool secondary structure; The difference of action site; Antisensenucleic acids is complementary to certain section sequence of gene transcription product mRNA, and decoy nucleic acid is incorporated on the gene transcription regulation factor (protein); Difference on the consumption: the genetic transcription of a copy goes out 200～300 mRNA, and mRNA has instantaneity, needs the antisensenucleic acids dose big, and on copy gene transcription regulatory factor only 1～several, need decoy nucleic acid dose few.
Because of the core sequence of decoy nucleic acid between 6～12 base pairs, the short easily degraded of chain, double-stranded unstable, easily unwind under the room temperature.No secondary space structure is difficult for and protein binding, thereby design needs suitably to increase base during medicine, the lengthening chain length, enhanced stability reaches the affinity with transcription factor, and wherein with structure the bests such as palindrome, hair clip, cross, stem ring, mute tinkling of pieces of jade shapes, so decoy nucleic acid is designed to contain between 15～55 bases of above-mentioned core sequence, can synthesize strand, selfing forms two strands and secondary structure thereof, but also each synthesizes two strands, and hybridization forms double-stranded.Because of nucleic acid is very easily lost activity by nuclease degradation in cell, therefore need modification protection, to strengthen anti-degradation capability, improve stability.Thio-modification is modal blocking group.
In sum, five class decoy nucleic acid of the present invention all have inhibitory action to tumor cell, in the antitumor drug exploitation, sizable application prospect is arranged, decoy nucleic acid drug of the present invention can close with pharmaceutical carrier, and pharmaceutical carrier comprises common carrier such as normal saline and buffer and liposome, polymer etc.
Description of drawings:
Fig. 1: the decoy nucleic acid of KGCD series is to the growth inhibited figure of tumor cell NCI-H460
Fig. 2: KGCD101a and KGCD102 decoy nucleic acid are to the growth inhibited figure of various cells
Fig. 3: KGCD101a and KGCD102 decoy nucleic acid are to the half lethal dose (IC of tumor cell NCI-H460
50) figure
As shown in Figure 1: the decoy nucleic acid experimental group that lung cancer cell line NCI-H460 is divided into positive controls, negative control group, blank group and six kinds of KGCD series, be inoculated in respectively 96 well culture plates in the RPMI RPMI-1640 that contains 10% hyclone, inoculation quantity is 2-3 * 104/ hole, cultivate after 24 hours, be replaced with serum-free medium, the blank group only adds 0.6 μ l/ hole empty liposome, all the other all add 0.6 μ l/ hole liposome is the different decoy nucleic acid of 200nM with final concentration, process after 5 hours, be replaced with the RPMI RPMI-1640 that contains 10% hyclone, at 37 ℃, 5%CO2Cultivate under the condition after 48 hours, with SRB dyeing, ELIASA is in λ510nmMeasure its OD value, and calculate cell survival rate, with sky White values of control groups is 1D0%, makes cell growth inhibition figure. As can be seen from Fig. 1: CRE represents the test of positive controls As a result, C represents the result of the test of negative control group, remaining the 6 groups examinations that are KGCD series decoy nucleic acid experimental group Test the result, this 6 groups of KGCD series decoy nucleic acid all demonstrate in various degree inhibitory action to the NCI-H460 cell, Wherein the inhibiting rate with KGCD101a and KGCD102 is the highest.
As shown in Figure 2: process respectively following tumor cell line with KGCD101a and KGCD102 decoy nucleic acid NCI--H460 (lung cancer), CNE (nasopharyngeal carcinoma), U251 (glioma), MCF-7 (breast Gland cancer), BEL-7402 (liver cancer) and normal cell strain: L-02 (liver cell) and NIH3T3 are the most shallow The look cylinder represents negative control group (mismatch), and is littler to various Growth of Cells impacts. And use KGCD101a With KGCD102 decoy nucleic acid various growth of tumour cell all there is in various degree inhibitory action, wherein U251 (glioma) and NCI-H460 (lung cancer) are suppressed maximum, and to the life of normal cell line Long impact is littler.
As shown in Figure 3: process tumour cell with the KGCD101a of variable concentrations and the decoy nucleic acid of KGCD102 NCI-H460, as seen from the figure: KGCD101a and KGCD102 are thin to NCI-H460 under the condition of low concentration Born of the same parents have inhibitory action, and their half lethal dose is 30～50nM, and negative control group then cell growth does not have dose difference.
The specific embodiment:
The preparation and the analysis of embodiment 1 decoy nucleic acid drug
Synthetic six kinds of following sulfo-decoy nucleic acid drug: KGCD101a (sequence 6), KGCD101b (sequence 10 and sequence 11) ' KGCD101c:(sequence 14 and sequence 15), KGCD102:(sequence 18), KGCD103a:(sequence 23 and sequence 24), KGCD103b (sequence 30).
Negative control sequence: 5 '-TGTGGTCATGTGGTCATGTGTCA-3 '
Positive control sequence: 5 '-TGACGTCATGACGTCATGACGTCA-3 '
The 391 type dna synthesizers that use U.S. applying biological Account Dept of PE company (Applied Biosystems) to make.Designed decoy nucleic acid with the synthetic sulfo-of phosphoramidite solid-phase synthesis.Primary raw material has: four kinds of diisopropyl β-cyanoethyl phosphoramidite monomers: adenosine (A), guanosine (G), cytidine (C), thymidine (T), four kinds of control aperture glass dust (CPG) solid phase synthesis posts (A, G, C, T).Synthetic scale is 10 micromoles.Block reagent is respectively: acetic anhydride/lutidines/oxolane and 1-Methylimidazole ./oxolane, thio reaction reagent: Beaucage reagent/acetonitrile, detritylation reagent: trichloroacetic acid/dichloromethane, liquid flux: acetonitrile and chloroform.The base monomer is dissolved in the anhydrous acetonitrile, and concentration is 100 mMs, and other reagent concentration and consumption all carry out according to the instrument handbook.Building-up process is by the programme-control of instrument own.Synthetic product is collected in the withstand voltage vial of sealing with strong aqua ammonia (29%), handles in 55 ℃ and sloughs various base blocking groups and amido protecting group on the nucleic acid molecules in 15 hours.Deprotection finishes the back volatilization and sloughs most of ammonia, and lyophilizing gets the white powder crude product, is dissolved in again in the buffer, carries out purification with Pharmacia Source 30 Q chromatographies and AKTA tomographic system.Purification of samples G-15 molecular sieve sephadex chromatography post desalination, lyophilizing gets the pure product of white cotton-shaped nucleic acid.Be stored in-20 ℃ of sample analyses that take a morsel: survey its purity and molecular weight and high performance liquid chromatography (HPLC) survey purity with high performance capillary electrophoresis and be more than 90%, it is entirely true that the dna sequencing method is measured sequence, and nuclear magnetic resonance method is surveyed the thioated degree greater than 98.5%.
2 six kinds of KGCD series of embodiment decoy nucleic acid is to the growth inhibited of pulmonary carcinoma NCI-H460 cell
The decoy nucleic acid experimental group that lung cancer cell line NCI-H460 is divided into positive controls, negative control group, blank group and six kinds of KGCD series, be inoculated in 96 well culture plates in the RPMI RPMI-1640 that contains 10% hyclone respectively, inoculation quantity is 2-3 * 10
4/ hole, cultivate after 24 hours, be replaced with serum-free medium, the blank group only adds 0.6 μ l/ hole empty liposome, all the other all add 0.6 μ l/ hole liposome is the different decoy nucleic acid of 200nM with final concentration, handle after 5 hours, be replaced with the RPMI RPMI-1640 that contains 10% hyclone, at 37 ℃, 5%CO
2Cultivate under the condition after 48 hours, with SRB dyeing, microplate reader is in λ
510nmMeasuring its OD value, and calculate cell survival rate, is 100% with blank group numerical value, makes cell growth inhibited figure.As seen from the figure: CRE represents the result of the test of positive controls, C represents the result of the test of negative control group, remaining the 6 groups result of the tests that are KGCD series decoy nucleic acid experimental group, this 6 kinds of KGCD series decoy nucleic acid all demonstrate in various degree inhibitory action to the NCI-H460 cell, and wherein the suppression ratio with KGCD101a and KGCD102 is the highest.
Embodiment 3 KGCD101a and KGCD102 decoy nucleic acid are to the growth inhibited of various cells
Handle following tumor cell line NCI-H460 (pulmonary carcinoma) respectively with KGCD101a and KGCD102 decoy nucleic acid, CNE (nasopharyngeal carcinoma), U251 (glioma), MCF-7 (breast carcinoma), BEL-7402 (hepatocarcinoma) and normal cell strain: L-02 (hepatocyte) and NIH3T3, the lightest cylinder is represented negative control group (mismatch), and is less to various cell growth effects.And various growth of tumour cell are all had in various degree inhibitory action with KGCD101a and KGCD102 decoy nucleic acid, and wherein U251 (glioma) and NCI-H460 (pulmonary carcinoma) are suppressed maximum, and less to the growth effect of normal cell strain.
Embodiment 4 medicine KGCD101a and KGCD102 are to the half lethal dose (IC of NCI-H460 cell
50)
KGCD101a and KGCD102 (5-200nM) with variable concentrations handle the NCI-H460 cell respectively, behind the cultivation certain hour, survey its OD value.From as Fig. 3 as can be seen, KGCD101a and KGCD102 have inhibitory action to cancerous cell under the condition of low concentration, and their half lethal dose is 30～50nM, is 30～50 μ g/ml, well below the standard (IC of screening anti-tumor medicine
50≤ 10 μ g/ml).
Embodiment 5 contains the pharmaceutical composition of decoy nucleic acid
Decoy nucleic acid medicine composition as animal and human's class vivo medicine-feeding is composed as follows:
Decoy nucleic acid KGCD101b:1mg/ml
Normal saline or phosphate buffer (PH 7.4): an amount of
Other youngster of the present invention plants nucleic acid and also adopts same prescription.
Sequence table
＜110〉Ye Qing
＜120〉genetic switch medicine for treating tumor
<160>32
<210>1
<211>9
<212>DNA
＜213〉artificial sequence
<400>1
stgacgtmr?9
<210>2
<211>8
<212>DNA
＜213〉artificial sequence
<400>2
stgastma?8
<210>3
<211>8
<212>DNA
＜213〉artificial sequence
<400>3
ttacctca?8
<210>4
<211>7
<212>DNA
＜213〉artificial sequence
<400>4
tctctta?7
<210>5
<211>12
<212>DNA
＜213〉artificial sequence
<400>5
raccacgtgg?ty?12
<210>6
<211>34
<212>DNA
＜213〉artificial sequence
<400>6
gcctgacgtc?aggggacttt?ccctgacgtc?aggc?34
<210>7
<211>24
<212>DNA
＜213〉artificial sequence
<400>7
gtttcgcggt?gacgtcaccc?tttc?24
<210>8
<211>24
<212>DNA
＜213〉artificial sequence
<400>8
gaaagggacg?tacgtccgcg?aaac?24
<210>9
<211>14
<212>DNA
＜213〉artificial sequence
<400>9
gaaaggcgcg?aaac?14
<210>10
<211>21
<212>DNA
＜213〉artificial sequence
<400>10
cgcttgc
tga?ctcagccgga?a?21
<210>11
<211>21
<212>DNA
＜213〉artificial sequence
<400>11
ttccggc
tga?gtcagcaagc?g?21
<210>12
<211>35
<212>DNA
＜213〉artificial sequence
<400>12
gatcg
tgact?cagcgcgatt?ttcgcgc
tga?gtcac?35
<210>13
<211>42
<212>DNA
＜213〉artificial sequence
<400>13
actctctcag?tc
tgactcat?gctctcagca?
tgagtcagac?tg?42
<210>14
<211>21
<212>DNA
＜213〉artificial sequence
<400>14
ctcaacc
tga?ctcagaaccc?t?21
<210>15
<211>21
<212>DNA
＜213〉artificial sequence
<400>15
agggttcact?cagtggttga?g?21
<210>16
<211>21
<212>DNA
＜213〉artificial sequence
<400>16
ccggggctga?ctcaggggca?a?21
<210>17
<211>23
<212>DNA
＜213〉artificial sequence
<400>17
ttgcccctaa?cggttagccc?cgg 23
<210>18
<211>37
<212>DNA
＜213〉artificial sequence
<400>18
ttacctcatt?acctcagccc?gtgaggtaat?gaggtaa?37
<210>19
<211>40
<212>DNA
＜213〉artificial sequence
<400>19
ttacctcatt?acctcattac?ctcatgaggt?aatgaggtaa?40
<210>20
<211>38
<212>DNA
＜213〉artificial sequence
<400>20
gagcccgtcg?ttacctcatc?agcccgtgat?gaggtaac?38
<210>21
<211>32
<212>DNA
＜213〉artificial sequence
<400>21
ttacctcatt?acgtcattac?gtcattacct?ca?32
<210>22
<211>22
<212>DNA
＜213〉artificial sequence
<400>22
tgaggtaatg?ataatgaggt?aa 22
<210>23
<211>26
<212>DNA
＜213〉artificial sequence
<400>23
tcaccatctc?ttatgcggtt?gaatag?26
<210>24
<211>26
<212>DNA
＜213〉artificial sequence
<400>24
ctattcaacc?gcataagaga?tggtga?26
<210>25
<211>35
<212>DNA
＜213〉artificial sequence
<400>25
tctcttatga?ctaatctctt?attagtcata?agaga?35
<210>26
<211>26
<212>DNA
＜213〉artificial sequence
<400>26
tctcttagct?ctcttagcct?ctctta?26
<210>27
<211>17
<212>DNA
＜213〉artificial sequence
<400>27
taagagaggc?taagaga?17
<210>28
<211>19
<212>DNA
＜213〉artificial sequence
<400>28
gagtctctta?ctcccgcgg 19
<210>29
<211>17
<212>DNA
＜213〉artificial sequence
<400>29
ccgcgggtct?cttagac?17
<210>30
<211>32
<212>DNA
＜213〉artificial sequence
<400>30
cacggaacga?gaccacgtgg?tctcgttccg?tg?32
<210>31
<211>24
<212>DNA
＜213〉artificial sequence
<400>31
ttctctgacc?acgtggtcct?cttc?24
<210>32
<211>23
<212>DNA
＜213〉artificial sequence
<400>32
gaagaggctc?tcttagcaga?gaa?23
Claims (6)
1 the present invention relates to a kind of genetic switch medicine for treating tumor, the composition characteristic of this medicine is one section sequence-specific dna oligo, its molecule primary structure is made up of the 15-55 that contains a RACCACGTGGTY core sequence nucleotide, and can form two strands and then form hair clip, false knot, stem ring, dumbbell, the multiple secondary structure of cross by selfing or mutual the friendship, comprise sequence 30---sequence 32.
The described genetic switch medicine for treating tumor of 2 claim 1 has 70% with its nucleic acid molecules and reaches above homologous sequence.
3 genetic switch medicine for treating tumor according to claim 1, the molecular characterization that it is characterized in that nucleic acid is the phosphodiester bond with any one base group modification in sulfenyl, methyl, the amide groups.
4 genetic switch medicine for treating tumor according to claim 1 is characterized in that dosage form comprises injection, oral, direct external application, transfection and transgenic.
The pharmaceutical composition that the described nucleotide sequence of 5 claim 1 is formed.
The described nucleotide sequence of 6 claim 1 is used for antitumor and prepares purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310113540 CN1251766C (en) | 2002-03-28 | 2002-03-28 | Tumour gene switch medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310113540 CN1251766C (en) | 2002-03-28 | 2002-03-28 | Tumour gene switch medicine |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021128189A Division CN1240439C (en) | 2002-03-28 | 2002-03-28 | Genetic switch medicine for treating tumor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1507875A true CN1507875A (en) | 2004-06-30 |
| CN1251766C CN1251766C (en) | 2006-04-19 |
Family
ID=34256850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310113540 Expired - Fee Related CN1251766C (en) | 2002-03-28 | 2002-03-28 | Tumour gene switch medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1251766C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016107115A1 (en) * | 2014-12-30 | 2016-07-07 | 南京艾德凯腾生物医药有限责任公司 | Oligomeric nucleic acid for preparing drugs for inhibiting tumour growth and use thereof |
-
2002
- 2002-03-28 CN CN 200310113540 patent/CN1251766C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016107115A1 (en) * | 2014-12-30 | 2016-07-07 | 南京艾德凯腾生物医药有限责任公司 | Oligomeric nucleic acid for preparing drugs for inhibiting tumour growth and use thereof |
| WO2016107118A1 (en) * | 2014-12-30 | 2016-07-07 | 南京艾德凯腾生物医药有限责任公司 | Oligomeric nucleic acid for preparing drugs for inhibiting tumour growth and use thereof |
| WO2016107117A1 (en) * | 2014-12-30 | 2016-07-07 | 南京艾德凯腾生物医药有限责任公司 | Oligomeric nucleic acid for preparing drugs for inhibiting tumour growth and use thereof |
| US10251907B2 (en) | 2014-12-30 | 2019-04-09 | Nanjing New Industry Investment Group Co., Ltd | Oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and application thereof |
| US10441600B2 (en) | 2014-12-30 | 2019-10-15 | Jiangsu Keygen Biotech Corp., Ltd | Oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and application thereof |
| US10525077B2 (en) | 2014-12-30 | 2020-01-07 | Jiangsu Keygen Biotech Corp., Ltd | Oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1251766C (en) | 2006-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1240439C (en) | Genetic switch medicine for treating tumor | |
| CN1630535A (en) | Inhibition of STAT-1 | |
| CN1904900A (en) | Human autogenous siRNA sequence, its application and screening method | |
| CN1084564A (en) | Antisense polynucleotides | |
| CN1252260C (en) | Tumor-specific promoters | |
| CN1219055C (en) | A specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it | |
| CN1701077A (en) | Use of antisense oligonucleotides to inhibit the expression of Akt-1 | |
| CN1251766C (en) | Tumour gene switch medicine | |
| CN1251765C (en) | Tumour gene switch medicine | |
| CN1251764C (en) | Tumour gene Switch medicine | |
| CN1948483A (en) | SiRNA for inhibiting human Rabj gene expression and its application | |
| CN1283793C (en) | Chemokine-like factor superfamily having skeletal muscle stimulating activity and immunoregulation function | |
| CN1295614A (en) | Modulator for function of receptor of TNF/NGF receptor family and other protein | |
| CN1809583A (en) | Antisense oligonucleotides that inhibit expression of hif-1 | |
| CN1740194A (en) | A kind of tumor correlated albumen and encoding gene thereof and application | |
| CN1124142A (en) | Oligonucleotides to inhibit the expression of isoprenyl protein transferases | |
| CN1580259A (en) | SiRAN and expression carrier for inhibiting human VEGF gene expression and their pharmaceutical use | |
| CN1244595C (en) | Tumor suppressor protein and its application | |
| CN1651450A (en) | Small interference RNA molecule (SiRNA) capable of effectively killing and wounding tumour cell pointed at PLK1 mRNA, its mixture and use | |
| CN1932016A (en) | Polynucleotide affecting SRE activity and its coding polypeptides and use | |
| CN1206242C (en) | Anti-angiogenesis and anti-cancer function of angiogenin combined with nucleotide | |
| CN1966684A (en) | Construction of HER2/neu mRNA in vitro transcription vector and use thereof | |
| CN1292078C (en) | Hepatic carcinoma tissue specific expression genes and use thereof | |
| CN1506117A (en) | Antitumor genetic transcription regulating medicine | |
| CN1233831C (en) | SiRNA and expression plasmid for inhibiting human bc1-2 gene expression and their use for preparing medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NANJING KAIJI BIOLOGY SCIENCE & TECHNOLOGY DEVELO Free format text: FORMER OWNER: YE QING Effective date: 20041001 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20041001 Address after: 210009, No. 238, Middle Road, Nanjing, Jiangsu Applicant after: Kaiji Biotech Development Co., Ltd., Nanjing Address before: 210002 room 486, No. 1901 East Zhongshan Road, Jiangsu, Nanjing Applicant before: Ye Qing |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060419 Termination date: 20110328 |